Global Peptide Therapeutics Market Research Report 2025

Publication ID:

PB505250317

Publication Date:

May 28, 2025

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global market for Peptide Therapeutics was valued at US$ 41000 million in the year 2024 and is projected to reach a revised size of US$ 74320 million by 2031, growing at a CAGR of 9.0% during the forecast period.
Peptide therapeutics are a class of pharmaceutical drugs composed of short chains of amino acids, typically ranging from 2 to 50 residues, that mimic natural peptides in the body. These drugs are designed to interact with specific cellular targets, such as receptors, enzymes, or ion channels, to regulate physiological functions. Due to their high specificity, low toxicity, and favorable safety profiles, peptide drugs are widely used in the treatment of various diseases, including cancer, diabetes, cardiovascular diseases, and infectious conditions. With advances in peptide engineering, formulation, and delivery technologies, peptide therapeutics have become a growing segment of the biopharmaceutical industry.
The Peptide Therapeutics market is driven by the increasing demand for highly specific and efficient treatments for a wide range of diseases, including cancer, diabetes, cardiovascular conditions, and rare genetic disorders. Peptides, due to their high selectivity, low immunogenicity, and close resemblance to natural biological molecules, are well-suited for targeted therapy with fewer side effects. Technological advancements in peptide synthesis, modification, and drug delivery systems have enhanced their stability and extended their half-life, making them more viable for clinical use. Additionally, the growing investment in biopharmaceutical research and development, along with a favorable regulatory environment for innovative therapies, is accelerating the development and approval of peptide-based drugs.
Despite these advantages, the Peptide Therapeutics market faces several challenges, particularly related to drug delivery and manufacturing. Peptides are generally unstable in the gastrointestinal tract and are rapidly degraded by enzymes, limiting their oral bioavailability and often requiring parenteral administration. This can affect patient compliance and limit market penetration. Moreover, the complex and costly manufacturing processes for peptide drugs, including synthesis, purification, and formulation, pose economic and technical barriers, especially for smaller biotech firms. Overcoming these limitations through innovative formulation strategies and cost-efficient production methods is critical for ensuring broader clinical adoption and long-term market growth.
Global Peptide Therapeutics key players include Sanofi, Novo Nordisk, Takeda, Eli Lilly, Ipsen, etc. Global top five manufacturers hold a share about 65%. North America is the largest market, with a share about 55%, followed by Europe and Asia-Pacific, both have a share about 40 percent. In terms of product, Injection is the largest segment, with a share about 70%. And in terms of application, the largest application is Cancer, followed by Central Nervous System.
This report aims to provide a comprehensive presentation of the global market for Peptide Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Peptide Therapeutics.
The Peptide Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Peptide Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Peptide Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Sanofi
Teva
Novo Nordisk
Takeda
Eli Lilly
AstraZeneca
Novartis
AbbVie
Ipsen
Ferring
Merck
The Medicines
J & J
Aurinia Pharmaceuticals
BioMarin Pharmaceutical
Apellis Pharmaceuticals
Lantheus
CSL Vifor Group
Segment by Type
Injection
Oral
Other
Segment by Application
Cancer
Metabolic Disorders
Central Nervous System
Other
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Peptide Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Peptide Therapeutics Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Injection
1.2.3 Oral
1.2.4 Other
1.3 Market by Application
1.3.1 Global Peptide Therapeutics Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Cancer
1.3.3 Metabolic Disorders
1.3.4 Central Nervous System
1.3.5 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Peptide Therapeutics Market Perspective (2020-2031)
2.2 Global Peptide Therapeutics Growth Trends by Region
2.2.1 Global Peptide Therapeutics Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Peptide Therapeutics Historic Market Size by Region (2020-2025)
2.2.3 Peptide Therapeutics Forecasted Market Size by Region (2026-2031)
2.3 Peptide Therapeutics Market Dynamics
2.3.1 Peptide Therapeutics Industry Trends
2.3.2 Peptide Therapeutics Market Drivers
2.3.3 Peptide Therapeutics Market Challenges
2.3.4 Peptide Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Peptide Therapeutics Players by Revenue
3.1.1 Global Top Peptide Therapeutics Players by Revenue (2020-2025)
3.1.2 Global Peptide Therapeutics Revenue Market Share by Players (2020-2025)
3.2 Global Top Peptide Therapeutics Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Peptide Therapeutics Revenue
3.4 Global Peptide Therapeutics Market Concentration Ratio
3.4.1 Global Peptide Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Peptide Therapeutics Revenue in 2024
3.5 Global Key Players of Peptide Therapeutics Head office and Area Served
3.6 Global Key Players of Peptide Therapeutics, Product and Application
3.7 Global Key Players of Peptide Therapeutics, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Peptide Therapeutics Breakdown Data by Type
4.1 Global Peptide Therapeutics Historic Market Size by Type (2020-2025)
4.2 Global Peptide Therapeutics Forecasted Market Size by Type (2026-2031)
5 Peptide Therapeutics Breakdown Data by Application
5.1 Global Peptide Therapeutics Historic Market Size by Application (2020-2025)
5.2 Global Peptide Therapeutics Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Peptide Therapeutics Market Size (2020-2031)
6.2 North America Peptide Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Peptide Therapeutics Market Size by Country (2020-2025)
6.4 North America Peptide Therapeutics Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Peptide Therapeutics Market Size (2020-2031)
7.2 Europe Peptide Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Peptide Therapeutics Market Size by Country (2020-2025)
7.4 Europe Peptide Therapeutics Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Peptide Therapeutics Market Size (2020-2031)
8.2 Asia-Pacific Peptide Therapeutics Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Peptide Therapeutics Market Size by Region (2020-2025)
8.4 Asia-Pacific Peptide Therapeutics Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Peptide Therapeutics Market Size (2020-2031)
9.2 Latin America Peptide Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Peptide Therapeutics Market Size by Country (2020-2025)
9.4 Latin America Peptide Therapeutics Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Peptide Therapeutics Market Size (2020-2031)
10.2 Middle East & Africa Peptide Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Peptide Therapeutics Market Size by Country (2020-2025)
10.4 Middle East & Africa Peptide Therapeutics Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Sanofi
11.1.1 Sanofi Company Details
11.1.2 Sanofi Business Overview
11.1.3 Sanofi Peptide Therapeutics Introduction
11.1.4 Sanofi Revenue in Peptide Therapeutics Business (2020-2025)
11.1.5 Sanofi Recent Development
11.2 Teva
11.2.1 Teva Company Details
11.2.2 Teva Business Overview
11.2.3 Teva Peptide Therapeutics Introduction
11.2.4 Teva Revenue in Peptide Therapeutics Business (2020-2025)
11.2.5 Teva Recent Development
11.3 Novo Nordisk
11.3.1 Novo Nordisk Company Details
11.3.2 Novo Nordisk Business Overview
11.3.3 Novo Nordisk Peptide Therapeutics Introduction
11.3.4 Novo Nordisk Revenue in Peptide Therapeutics Business (2020-2025)
11.3.5 Novo Nordisk Recent Development
11.4 Takeda
11.4.1 Takeda Company Details
11.4.2 Takeda Business Overview
11.4.3 Takeda Peptide Therapeutics Introduction
11.4.4 Takeda Revenue in Peptide Therapeutics Business (2020-2025)
11.4.5 Takeda Recent Development
11.5 Eli Lilly
11.5.1 Eli Lilly Company Details
11.5.2 Eli Lilly Business Overview
11.5.3 Eli Lilly Peptide Therapeutics Introduction
11.5.4 Eli Lilly Revenue in Peptide Therapeutics Business (2020-2025)
11.5.5 Eli Lilly Recent Development
11.6 AstraZeneca
11.6.1 AstraZeneca Company Details
11.6.2 AstraZeneca Business Overview
11.6.3 AstraZeneca Peptide Therapeutics Introduction
11.6.4 AstraZeneca Revenue in Peptide Therapeutics Business (2020-2025)
11.6.5 AstraZeneca Recent Development
11.7 Novartis
11.7.1 Novartis Company Details
11.7.2 Novartis Business Overview
11.7.3 Novartis Peptide Therapeutics Introduction
11.7.4 Novartis Revenue in Peptide Therapeutics Business (2020-2025)
11.7.5 Novartis Recent Development
11.8 AbbVie
11.8.1 AbbVie Company Details
11.8.2 AbbVie Business Overview
11.8.3 AbbVie Peptide Therapeutics Introduction
11.8.4 AbbVie Revenue in Peptide Therapeutics Business (2020-2025)
11.8.5 AbbVie Recent Development
11.9 Ipsen
11.9.1 Ipsen Company Details
11.9.2 Ipsen Business Overview
11.9.3 Ipsen Peptide Therapeutics Introduction
11.9.4 Ipsen Revenue in Peptide Therapeutics Business (2020-2025)
11.9.5 Ipsen Recent Development
11.10 Ferring
11.10.1 Ferring Company Details
11.10.2 Ferring Business Overview
11.10.3 Ferring Peptide Therapeutics Introduction
11.10.4 Ferring Revenue in Peptide Therapeutics Business (2020-2025)
11.10.5 Ferring Recent Development
11.11 Merck
11.11.1 Merck Company Details
11.11.2 Merck Business Overview
11.11.3 Merck Peptide Therapeutics Introduction
11.11.4 Merck Revenue in Peptide Therapeutics Business (2020-2025)
11.11.5 Merck Recent Development
11.12 The Medicines
11.12.1 The Medicines Company Details
11.12.2 The Medicines Business Overview
11.12.3 The Medicines Peptide Therapeutics Introduction
11.12.4 The Medicines Revenue in Peptide Therapeutics Business (2020-2025)
11.12.5 The Medicines Recent Development
11.13 J & J
11.13.1 J & J Company Details
11.13.2 J & J Business Overview
11.13.3 J & J Peptide Therapeutics Introduction
11.13.4 J & J Revenue in Peptide Therapeutics Business (2020-2025)
11.13.5 J & J Recent Development
11.14 Aurinia Pharmaceuticals
11.14.1 Aurinia Pharmaceuticals Company Details
11.14.2 Aurinia Pharmaceuticals Business Overview
11.14.3 Aurinia Pharmaceuticals Peptide Therapeutics Introduction
11.14.4 Aurinia Pharmaceuticals Revenue in Peptide Therapeutics Business (2020-2025)
11.14.5 Aurinia Pharmaceuticals Recent Development
11.15 BioMarin Pharmaceutical
11.15.1 BioMarin Pharmaceutical Company Details
11.15.2 BioMarin Pharmaceutical Business Overview
11.15.3 BioMarin Pharmaceutical Peptide Therapeutics Introduction
11.15.4 BioMarin Pharmaceutical Revenue in Peptide Therapeutics Business (2020-2025)
11.15.5 BioMarin Pharmaceutical Recent Development
11.16 Apellis Pharmaceuticals
11.16.1 Apellis Pharmaceuticals Company Details
11.16.2 Apellis Pharmaceuticals Business Overview
11.16.3 Apellis Pharmaceuticals Peptide Therapeutics Introduction
11.16.4 Apellis Pharmaceuticals Revenue in Peptide Therapeutics Business (2020-2025)
11.16.5 Apellis Pharmaceuticals Recent Development
11.17 Lantheus
11.17.1 Lantheus Company Details
11.17.2 Lantheus Business Overview
11.17.3 Lantheus Peptide Therapeutics Introduction
11.17.4 Lantheus Revenue in Peptide Therapeutics Business (2020-2025)
11.17.5 Lantheus Recent Development
11.18 CSL Vifor Group
11.18.1 CSL Vifor Group Company Details
11.18.2 CSL Vifor Group Business Overview
11.18.3 CSL Vifor Group Peptide Therapeutics Introduction
11.18.4 CSL Vifor Group Revenue in Peptide Therapeutics Business (2020-2025)
11.18.5 CSL Vifor Group Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer

Companies Mentioned:

Sanofi
Teva
Novo Nordisk
Takeda
Eli Lilly
AstraZeneca
Novartis
AbbVie
Ipsen
Ferring
Merck
The Medicines
J & J
Aurinia Pharmaceuticals
BioMarin Pharmaceutical
Apellis Pharmaceuticals
Lantheus
CSL Vifor Group

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂